Eric Poma, Ph.D.
Chief Executive Officer & Chief Scientific Officer
Eric Poma, Ph.D. has served as Molecular Templates’ Chief Executive Officer and Chief Scientific Officer since the Company’s inception in 2009. From March 2005 until September 2008, Dr. Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems. (now Eli Lilly and Company) a biotechnology company focused on antibody therapeutics. As the founder and in his role as Chief Scientific Officer at Molecular Templates, he led the invention of the technology underlying Molecular Templates’ platform technology and what constitutes the whole of Molecular Templates’ current lead and preclinical pipeline candidates. Dr. Poma received his Doctor of Philosophy in Microbiology and Immunology and Bachelor of Arts in Biology from the University of North Carolina at Chapel Hill and his Master of Business Administration from New York University.
President & Chief Financial Officer
Jason Kim joined Molecular Templates in 2010 and serves as President and Chief Financial Officer. He previously served as Chief Operating Officer. He also served as Molecular Templates’ President and Chief Financial Officer from February 2010 to August 2017. Previously, Mr. Kim led corporate development and strategic planning initiatives at OSI Pharmaceuticals and ImClone Systems. He served as an investment professional at Domain Associates and Safeguard Scientifics where he focused on venture and public investments in biotechnology. Mr. Kim holds a Master of Business Administration from The Wharton School and a Bachelor of Arts in Neuroscience from Wesleyan University.
Dr. Maurizio Voi
Chief Medical Officer
Dr. Voi joins MTEM from Novartis, where he served as Vice President, Global Program Head, for the PD-1 antibody Tislelizumab since April 2021. He was previously Global Program Head, Melanoma, at Novartis, a position he held since June 2017, and Vice President Global Clinical Program Head from August 2013 until June 2017 responsible for the clinical development of Kisqali®, Afinitor® and Votrient®, as well as other novel immuno-therapy compounds. Previous to Novartis, Dr. Voi was Chief Medical and Development Officer at Curis, where he was responsible for all Research & Development activities ranging from early drug discovery, to IND filings, to the development of clinical stage assets in oncology. Prior to Curis, Dr. Voi held strategic global roles in oncology drug development at Pfizer, Bristol Myers Squibb and Eli Lilly. He has published close to 40 articles in peer-reviewed journals, primarily in the areas of early-stage drug development and the treatment of solid tumors. Dr. Voi received his M.D. in 1985 from the University of Padua, School of Medicine in Italy.
Chief Operating Officer
Kristen Quigley joined Molecular Templates in 2017 and serves as Chief Operating Officer. She previously served as Senior Vice President of Clinical Operations. She has 27 years of clinical research experience, including 24 years in phase I-IV clinical trial and project management, and over 6 years in executive roles. Kristen served in Vice President/ Senior Vice President of Clinical Operations roles at two biotech companies prior to joining Molecular Templates, she co-directed the Nordic region for a large global CRO, and she has successfully governed clinical development portfolios worth as much as $147M. Ms. Quigley holds a Bachelor of Arts in Psychology from Washington University in St. Louis.
Chief Strategy Officer & Head of Investor Relations
Dr. Grace Kim joined Molecular Templates in 2022 and serves as Chief Strategy Officer and Head of Investor Relations. She has 20 years of experience driving investor strategy, corporate strategy, and business development. Previously, she led two biopharma advisories in Senior Vice President and Founder roles and served on matrixed leadership teams. Companies she worked with include BeiGene, BioMarin, Cullinan Oncology, Celularity, Aimmune (Nestlé), and others. Dr. Kim earned a doctorate in pharmacology from the University of Florida with post-doc immunology training and graduate studies at the University of Chicago. She is published in Nature Clinical Oncology and holds an adjunct faculty position at Columbia University.
Joseph Phillips, Ph.D.
Senior Vice President and Head of CMC Development
Joseph Phillips, Ph.D. joined Molecular Templates in June 2020 and serves as Senior Vice President and Head of CMC Development. Before joining Molecular Templates, he was Senior Vice President and Head of Pharmaceutical Development at ArmaGen, Inc., leading CMC, manufacturing and clinical supply operations for biologic therapeutics developed for neurological disorders and neurodegenerative diseases. Prior to ArmaGen, Dr. Phillips was an independent consultant providing expertise in bioprocess and product development, manufacturability, QbD, cGMP production, technical operations, quality and global CMC submissions. Previously, he was at Amgen, Inc. serving in several leadership roles in process and product development associated with the successful implementation of platform manufacturing processes and application of single-use manufacturing technology. Before joining Amgen, Mr. Phillips worked at The Upjohn Company (Pfizer/Pharmacia) and GSK in drug substance and drug product development. Mr. Phillips received his Ph.D. in pharmaceutics and analytical chemistry from University of Brighton (UK), his M.Sc. in organometallic chemistry from University of Sussex (UK) and his B.Sc. in applied chemistry from University of Brighton (UK).